40 results on '"Puc, Matthew"'
Search Results
2. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
- Author
-
Burns, Laura, Hsu, Chih-Yuan, Whisenant, Jennifer G., Marmarelis, Melina E., Presley, Carolyn J., Reckamp, Karen L., Khan, Hina, Jo Fidler, Mary, Bestvina, Christine M., Brahmer, Julie, Puri, Sonam, Patel, Jyoti D., Halmos, Balazs, Hirsch, Fred R., Liu, Stephen V., Costa, Daniel B., Goldberg, Sarah B., Feldman, Lawrence E., Mamdani, Hirva, Puc, Matthew, Mansfield, Aaron S., Islam, Nahida, Scilla, Katherine A., Garassino, Marina C., Horn, Leora, Peters, Solange, Wakelee, Heather A., Charlot, Marjory, and Tapan, Umit
- Published
- 2023
- Full Text
- View/download PDF
3. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium
- Author
-
Choueiri, Toni K., Labaki, Chris, Bakouny, Ziad, Hsu, Chih-Yuan, Schmidt, Andrew L., de Lima Lopes, Gilberto, Jr., Hwang, Clara, Singh, Sunny R.K., Jani, Chinmay, Weissmann, Lisa B., Griffiths, Elizabeth A., Halabi, Susan, Wu, Ulysses, Berg, Stephanie, O'Connor, Timothy E., Wise-Draper, Trisha M., Panagiotou, Orestis A., Klein, Elizabeth J., Joshi, Monika, Yared, Fares, Dutra, Miriam Santos, Gatson, Na Tosha N., Blau, Sibel, Singh, Harpreet, Nanchal, Rahul, McKay, Rana R., Nonato, Taylor K., Quinn, Ryann, Rubinstein, Samuel M., Puc, Matthew, Mavromatis, Blanche H., Vikas, Praveen, Faller, Bryan, Zaren, Howard A., Del Prete, Salvatore, Russell, Karen, Reuben, Daniel Y., Accordino, Melissa K., Friese, Christopher R., Mishra, Sanjay, Rivera, Donna R., Shyr, Yu, Farmakiotis, Dimitrios, and Warner, Jeremy L.
- Published
- 2023
- Full Text
- View/download PDF
4. Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium
- Author
-
Elkrief, Arielle, Hennessy, Cassandra, Kuderer, Nicole M, Rubinstein, Samuel M, Wulff-Burchfield, Elizabeth, Rosovsky, Rachel P, Vega-Luna, Karen, Thompson, Michael A, Panagiotou, Orestis A, Desai, Aakash, Rivera, Donna R, Khaki, Ali Raza, Tachiki, Lisa, Lynch, Ryan C, Stratton, Catherine, Elias, Rawad, Batist, Gerald, Kasi, Anup, Shah, Dimpy P, Bakouny, Ziad, Cabal, Angelo, Clement, Jessica, Crowell, Jennifer, Dixon, Becky, Friese, Christopher R, Fry, Stacy L, Grover, Punita, Gulati, Shuchi, Gupta, Shilpa, Hwang, Clara, Khan, Hina, Kim, Soo Jung, Klein, Elizabeth J, Labaki, Chris, McKay, Rana R, Nizam, Amanda, Pennell, Nathan A, Puc, Matthew, Schmidt, Andrew L, Shahrokni, Armin, Shaya, Justin A, Su, Christopher T, Wall, Sarah, Williams, Nicole, Wise-Draper, Trisha M, Mishra, Sanjay, Grivas, Petros, French, Benjamin, Warner, Jeremy L, and Wildes, Tanya M
- Published
- 2022
- Full Text
- View/download PDF
5. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- Author
-
Abidi, Maheen, Acoba, Jared D., Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H., Azad, Nilo, Bar, Michael H., Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H., Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W., Busser, Fiona, Cabal, Angelo, Caimi, Paolo, Carducci, Theresa, Casulo, Carla, Chen, James L., Clement, Jessica M, Chism, David, Cook, Erin, Curran, Catherine, Daher, Ahmad, Dailey, Mark, Dahiya, Saurabh, Deeken, John, Demetri, George D., DiLullo, Sandy, Duma, Narjust, Elias, Rawad, Faller, Bryan, Fecher, Leslie A., Feldman, Lawrence E., Friese, Christopher R., Fu, Paul, Fu, Julie, Futreal, Andy, Gainor, Justin, Garcia, Jorge, Gill, David M., Gillaspie, Erin A., Giordano, Antonio, Glace, (Mary) Grace, Grothey, Axel, Gulati, Shuchi, Gurley, Michael, Halmos, Balazs, Herbst, Roy, Hershman, Dawn, Hoskins, Kent, Jain, Rohit K., Jabbour, Salma, Jha, Alokkumar, Johnson, Douglas B., Joshi, Monika, Kelleher, Kaitlin, Kharofa, Jordan, Khan, Hina, Knoble, Jeanna, Koshkin, Vadim S., Kulkarni, Amit A., Lammers, Philip E., Leighton, John C., Jr, Lewis, Mark A., Li, Xuanyi, Li, Ang, Lo, K.M. Steve, Loaiza-Bonilla, Arturo, LoRusso, Patricia, Low, Clarke A., Lustberg, Maryam B., Mahadevan, Daruka, Mansoor, Abdul-Hai, Marcum, Michelle, Markham, Merry Jennifer, Handy Marshall, Catherine, Mashru, Sandeep H., Matar, Sara, McNair, Christopher, McWeeney, Shannon, Mehnert, Janice M., Menendez, Alvaro, Menon, Harry, Messmer, Marcus, Monahan, Ryan, Mushtaq, Sarah, Nagaraj, Gayathri, Nagle, Sarah, Naidoo, Jarushka, Nakayama, John M., Narayan, Vikram, Nelson, Heather H., Nemecek, Eneida R., Nguyen, Ryan, Nuzzo, Pier Vitale, Oberstein, Paul E., Olszewski, Adam J., Owenby, Susie, Pasquinelli, Mary M., Philip, John, Prabhakaran, Sabitha, Puc, Matthew, Ramirez, Amelie, Rathmann, Joerg, Revankar, Sanjay G., Rho, Young Soo, Rhodes, Terence D., Rice, Robert L., Riely, Gregory J., Riess, Jonathan, Rink, Cameron, Robilotti, Elizabeth V., Rosenstein, Lori, Routy, Bertrand, Rovito, Marc A., Saif, M. Wasif, Sanyal, Amit, Schapira, Lidia, Schwartz, Candice, Serrano, Oscar, Shah, Mansi, Shah, Chintan, Shaw, Grace, Shergill, Ardaman, Shouse, Geoffrey, Soares, Heloisa P., Solorzano, Carmen C., Srivastava, Pramod K., Stauffer, Karen, Stover, Daniel G., Stratton, Jamie, Stratton, Catherine, Subbiah, Vivek, Tamimi, Rulla, Tannir, Nizar M., Topaloglu, Umit, Van Allen, Eli, Van Loon, Susan, Vega-Luna, Karen, Venepalli, Neeta, Verma, Amit K., Vikas, Praveen, Wall, Sarah, Weinstein, Paul L., Weiss, Matthias, Wise-Draper, Trisha, Wood, William A., Xu, Wenxin (Vincent), Yackzan, Susan, Zacks, Rosemary, Zhang, Tian, Zimmer, Andrea J., West, Jack, Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Jr, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, and Warner, Jeremy L
- Published
- 2020
- Full Text
- View/download PDF
6. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease
- Author
-
Moey, Melissa Y.Y., Hennessy, Cassandra, French, Benjamin, Warner, Jeremy L., Tucker, Matthew D., Hausrath, Daniel J., Shah, Dimpy P., DeCara, Jeanne M., Bakouny, Ziad, Labaki, Chris, Choueiri, Toni K., Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar S., Awosika, Joy A., Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie A., Gomez, Cyndi Gonzalez, Hayes-Lattin, Brandon, Glover, Michael J., Shah, Sumit A., Gopalakrishnan, Dharmesh, Griffiths, Elizabeth A., Kwon, Daniel H., Koshkin, Vadim S., Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana R., Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth M., Xie, Zhuoer, Halfdanarson, Thorvardur R., Farmakiotis, Dimitrios, Klein, Elizabeth J., Robilotti, Elizabeth V., Riely, Gregory J., Durand, Jean-Bernard, Hayek, Salim S., Kondapalli, Lavanya, Berg, Stephanie, O'Connor, Timothy E., Bilen, Mehmet A., Castellano, Cecilia, Accordino, Melissa K., Sibel, Blau, Weissmann, Lisa B., Jani, Chinmay, Flora, Daniel B., Rudski, Lawrence, Dutra, Miriam Santos, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju
- Published
- 2023
- Full Text
- View/download PDF
7. Surface Modifications of Mechanical Heart Valves : Effects on Thrombogenicity
- Author
-
Tran, Hoang S., Puc, Matthew M., Chrzanowski, Frank A., Jr., Hewitt, Charles W., Soll, David B., Singh, Bawa, Kumar, Nalin, Marra, Steven, Simonetti, Vincent, Cilley, Jonathan, DelRossi, Anthony J., Wise, Donald L., editor, Gresser, Joseph D., editor, Trantolo, Debra J., editor, Cattaneo, Mario V., editor, Lewandrowski, Kai-Uwe, editor, and Yaszemski, Michael J., editor
- Published
- 2000
- Full Text
- View/download PDF
8. Improved Survival after Pulmonary Metastasectomy for Soft Tissue Sarcoma
- Author
-
Predina, Jarrod D., Puc, Matthew M., Bergey, Meredith R., Sonnad, Seema S., Kucharczuk, John C., Staddon, Arthur, Kaiser, Larry R., and Shrager, Joseph B.
- Published
- 2011
- Full Text
- View/download PDF
9. Early Outcomes After Bilateral Thoracoscopy Versus Median Sternotomy for Lung Volume Reduction
- Author
-
Puc, Matthew M., Sonnad, Seema S., and Shrager, Joseph B.
- Published
- 2010
- Full Text
- View/download PDF
10. Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis
- Author
-
Kulkarni, Amit A., Hennessy, Cassandra, Wilson, Grace, Ramesh, Vidhyalakshmi, Hwang, Clara, Awosika, Joy, Bakouny, Ziad, Khan, Hina, Vilar-Compte, Diana, McKay, Rana, Jani, Chinmay, Weissmann, Lisa, Griffiths, Elizabeth, Batist, Gerald, Bouganim, Nathaniel, Mavromatis, Blanche, Bashir, Babar, Nguyen, Ryan H., Riess, Jonathan W., Puc, Matthew, Kasi, Anup, Berg, Stephanie, Castillo, Dan Ran, Hayes-Lattin, Brandon, Hosmer, Wylie, Flora, Daniel, Mishra, Sanjay, French, Benjamin, Warner, Jeremy L., Lopes, Gilberto, Peters, Solange, and Florez, Narjust
- Published
- 2024
- Full Text
- View/download PDF
11. Preoperative Chemotherapy-Sensitized Radiation Therapy for Cervical Metastases in Head and Neck Cancer
- Author
-
Puc, Matthew M., Chrzanowski, Francis A., Jr, Tran, Hoang S., Liu, Li, Glicksman, Arvin S., Landman, Christine, and Slotman, Gus J.
- Published
- 2000
12. Bleeding Complications in Patients with Cancer and COVID 19- Analysis from the COVID 19and Cancer Consortium (CCC19) Registry
- Author
-
Shah, Surbhi, Gulati, Shuchi, Li, Ang, Fu, Julie, Kumar, Vaibhav, Zon, Rebecca, Kulkarni, Amit, Shah, Pankil, Byeff, Peter D., Nguyen, Ryan, Nagaraj, Gayathri, Puc, Matthew, Hwang, Clara, McKay, Rana, French, Benjamin, Hennessy, Cassandra, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., and Rosovsky, Rachel P.
- Published
- 2021
- Full Text
- View/download PDF
13. BioGlue surgical adhesive for thoracic aortic repair during coagulopathy: efficacy and histopathology
- Author
-
Hewitt, Charles W, Marra, Steven W, Kann, Brian R, Tran, Hoang S, Puc, Matthew M, Chrzanowski, Frank A, Jr, Tran, Jean-Luc V, Lenz, Steven D, Cilley, Jonathan H, Jr, Simonetti, Vincent A, and DelRossi, Anthony J
- Published
- 2001
- Full Text
- View/download PDF
14. Ten-year experience with Mersilene-reinforced sternal wound closure
- Author
-
Puc, Matthew M, Antinori, Charles H, Villanueva, Dioscoro T, Tarnoff, Michael, and Heim, John A
- Published
- 2000
- Full Text
- View/download PDF
15. Predictors of operative outcome in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome
- Author
-
Tran, Hoang S, Moncure, Michael, Tarnoff, Michael, Goodman, Martin, Puc, Matthew M, Kroon, David, Eydelman, Julia, and Ross, Steven E
- Published
- 2000
- Full Text
- View/download PDF
16. Site-Specific Immunosuppression using a New Formulation of Topical Cyclosporine A with Polyethylene Glycol-8 Glyceryl Caprylate/Caprate
- Author
-
Tran, Hoang S., Malli, Dipak, Chrzanowski, Francis A., Puc, Matthew M., Matthews, Martha S., and Hewitt, Charles W.
- Published
- 1999
- Full Text
- View/download PDF
17. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
- Author
-
Abidi, Maheen, Aboulafia, David M., Accordino, Melissa K., Acoba, Jared D., Ahluwalia, Manmeet S., Ahmad, Syed A., Ajmera, Archana, Alimohamed, Saif I., Altman, Jessica, Angevine, Anne H., Bakouny, Ziad, Bar, Michael H., Bardia, Aditya, Barnholtz-Sloan, Jill S., Barrow McCollough, Briana, Bashir, Babar, Batist, Gerald, Bekaii-Saab, Tanios S., Berg, Stephanie, Bernicker, Eric H., Bhutani, Divaya, Bilen, Mehmet A., Bindal, Poorva, Bishnoi, Rohit, Blau, Sibel, Bohachek, Pamela, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bouganim, Nathaniel, Bowles, Daniel W., Busser, Fiona J., Butt, Omar, Cabal, Angelo, Cabalona, Wilhelmina D., Cabebe, Elwyn C., Caimi, Paolo, Campian, Jian L., Carducci, Theresa M., Chen, James L., Cheng, Alex, Chism, David D., Choueiri, Toni K., Clark, Melanie J., Clement, Jessica M., Connors, Jean M., Cook, Erin, Curran, Catherine R., Daher, Ahmad, Dailey, Mark E., Davis, Elizabeth J., Dawsey, Scott J., Deeken, John F., Del Prete, Salvatore A., Demetri, George D., Desai, Aakash, Doroshow, Deborah B., Durbin, Eric B., Egan, Pamela C., Elias, Rawad, Elkrief, Arielle, Elms, Destry J., Elshoury, Amro, Faller, Bryan, Farmakiotis, Dimitrios, Fecher, Leslie A., Feldman, Lawrence E., Ferrario, Cristiano, Fiala, Mark A., Flora, Daniel B., French, Benjamin, Friese, Christopher R., Fu, Julie C., Gadgeel, Shirish M., Gainor, Justin, Galsky, Matthew D., Gantt, Gerald, Jr., Garcia, Jorge A., Gartrell, Benjamin A., Gatti-Mays, Margaret E., Gill, David M., Gillaspie, Erin A., Giordano, Antonio, Glace, (Mary) Grace, Glover, Michael J., Goel, Sanjay, Graber, Jerome J., Griffiths, Elizabeth A., Grivas, Petros, Grover, Punita, Gulati, Anthony P., Gulati, Shuchi, Gupta, Shilpa, Gurley, Michael, Hafez, Navid, Halabi, Susan, Halfdanarson, Thorvardur R., Halmos, Balazs, Hausrath, Daniel J., Hawley, Jessica E., Hennessy, Cassandra, Herbst, Roy S., Hershman, Dawn L., Hoppenot, Claire, Hoskins, Kent F., Hoyo-Ulloa, Irma, Hsu, Emily, Hsu, Chih-Yuan, Hwang, Clara, Islam, Jessica Yasmine, Jabbour, Salma K., Jani, Chinmay, Jha, Alokkumar, Jhawar, Sachin R., Johnson, Douglas B., Joshi, Monika, Kasi, Anup, Kelleher, Kaitlin, Kennecke, Hagen F., Khaki, Ali Raza, Khan, Hina, Khan, Mahir, Kharofa, Jordan, Kloecker, Goetz, Knoble, Jeanna L., Kulkarni, Amit A., Kumar, Vaibhav, Lammers, Philip E., Leighton, John C., Jr., Lemmon, Christopher A., Lewis, Mark A., Li, Ang, Li, Xuanyi, Liu, Stephen V., Lo, K.M., Loaiza-Bonilla, Arturo, Logan, Barbara B., Loggers, Elizabeth T., de Lima Lopes, Gilberto, Jr., Loree, Jonathan M., LoRusso, Patricia, Low, Clarke A., Lustberg, Maryam B., Lyman, Gary H., Lynch, Ryan C., Madhavan, Subha, Mahadevan, Daruka, Mahmood, Sana Z., Mansoor, Abdul-Hai, Marcum, Michelle, Markham, Merry-Jennifer, Mashru, Sandeep H., Masters, Tyler, Mavromatis, Blanche H., McKay, Rana R., McNair, Christopher, McWeeney, Shannon, Menendez, Alvaro G., Menon, Harry, Mesa, Ruben A., Mico, Vasil, Miller, Chaim, Mishra, Sanjay, Monahan, Ryan S., Morgans, Alicia K., Mulcahy, Mary F., Mundt, Daniel, Mushtaq, Sarah, Nagaraj, Gayathri, Nagle, Sarah, Nakasone, Elizabeth S., Nakayama, John M., Nelson, Heather H., Nemecek, Eneida R., Nguyen, Ryan H., Nizam, Amanda, Nohria, Anju, Nuzzo, Pier Vitale, Ohri, Nitin, Olszewski, Adam J., Owenby, Susie, Painter, Corrie A., Palmer, Joshua D., Panagiotou, Orestis A., Park, Cathleen, Pasquinelli, Mary M., Patel, Jaymin M., Patel, Kanishka G., Peddi, Prakash, Pennell, Nathan A., Peters, Solange, Pilar, Christine, Pillainayagam, Clement, Puc, Matthew, Ramirez, Amelie G., Rathmann, Joerg, Ravindranathan, Deepak, Reid, Sonya A., Reuben, Daniel Y., Revankar, Sanjay G., Reynolds, Kerry L., Rho, Young Soo, Rhodes, Terence D., Rice, Robert L., Riess, Jonathan, Rini, Brian I., Rink, Cameron, Rosen, Lane R., Rosenstein, Lori J., Rosovsky, Rachel P., Routy, Bertrand, Rovito, Marc A., Rubinstein, Samuel M., Saif, M. Wasif, Salazar, Mary, Santos Dutra, Miriam, Schapira, Lidia, Schmidt, Andrew L., Schroeder, Brett A., Schwartz, Gary K., Schwartz, Candice, Schweizer, Michael T., Serrano, Oscar K., Shafer, Danielle A., Shah, Pankil K., Shah, Dimpy, Shah, Mansi R., Shah, Sumit A., Shah, Chintan, Shaw, Grace, Shaya, Justin A., Shyr, Yu, Slosky, David A., Smits, Melissa, Solorzano, Carmen C., Stauffer, Karen, Stockerl-Goldstein, Keith E., Stover, Daniel G., Stratton, Jamie, Stratton, Catherine, Streckfuss, Mitrianna, Subbiah, Suki, Tachiki, Lisa, Tadesse, Eyob, Thompson, Michael A., Topaloglu, Umit, Tucker, Matthew D., Van Allen, Eliezer M., Van Loon, Susan, Vega-Luna, Karen, Venepalli, Neeta K., Verma, Amit, Vikas, Praveen, Vinayak, Shaveta, Vinh, Donald C., Wagner, Michael J., Wall, Sarah, Wang, Lucy L., Warner, Jeremy L., Wehbe, Firas H., Weinstein, Paul L., Weiss, Matthias, Weissmann, Lisa B., Wildes, Tanya M., Williams, Nicole, Wise-Draper, Trisha M., Wood, William A., Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth M., Xie, Zhuoer, Xu, Wenxin, Yeh, Albert C., Yu, Irene S., Yu, Peter Paul, Zacks, Rosemary, Zaman, Qamar Ul, Zaren, Howard, Zhang, Tian, Zhou, Alice Y., Zhu, Huili, Zon, Rebecca L., and Zubiri, Leyre
- Published
- 2020
- Full Text
- View/download PDF
18. Preoperative CHA2 DS2 -VASc Score Predicts Postoperative Atrial Fibrillation after Lobectomy.
- Author
-
Lee, Charles T., Strauss, David M., Stone, Lauren E., Stoltzfus, Jill C., Puc, Matthew M., and Burfeind, William R.
- Subjects
LOBECTOMY (Lung surgery) ,ATRIAL fibrillation - Abstract
Background Postoperative atrial fibrillation (POAF) affects 10 to 20% of noncardiac thoracic surgeries and increases patient morbidity and costs. The purpose of this study is to determine if preoperative CHA
2 DS2 -VASc score can predict POAF after pulmonary lobectomy for nonsmall cell lung cancer. Methods Patients with complete CHA2 DS2 -VASc data who underwent lobectomies from January 2007 to January 2016 at a single institution were analyzed in a retrospective case–control study using a prospective database. An independent samples t -test was used to compare the mean CHA2 DS2 -VASc scores of POAF and non-POAF groups. A multivariable logistic regression analysis (MVA) evaluated the independent contribution of variables of the CHA2 DS2 -VASc score in predicting POAF. Chi-square test with univariate odds ratios (ORs) was used to determine a statistically significant cutoff score for predicting POAF. Results Of 525 total patients, 82 (15.6%) developed POAF (mean CHA2 DS2 -VASc score: 2.7) and 443 (84.4%) did not develop POAF (mean score: 2.3). Mean difference between these groups was significant at 0.43 (p = 0.01; 95% confidence interval [CI]: 0.09–0.76). In the MVA, significant predictors of POAF were age 65 to 74 years (adjusted OR [aOR] = 2.45; 95% CI: 1.31–4.70; p = 0.006) and age ≥75 years (aOR = 3.11; 95% CI: 1.62–5.95; p = 0.0006). Patients with CHA2 DS2 -VASc scores ≥5 had significantly increased OR for POAF (OR = 2.59; 95% CI: 1.22–5.50). Conclusions Preoperatively calculated CHA2 DS2 -VASc score can predict POAF in patients undergoing pulmonary lobectomy. Age is the most statistically significant independent predictor, and patients with scores ≥5 have significantly increased risk. Trials for POAF prophylaxis should target this population. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
19. Intradiaphragmatic Bronchogenic Cysts: Case Report and Systematic Review.
- Author
-
Mubang, Ronnie, Brady, John Joseph, Mao, Melissa, Burfeind, William, and Puc, Matthew
- Subjects
CYSTS (Pathology) ,BRONCHIAL diseases ,DIAPHRAGM diseases ,SURGICAL excision ,SYSTEMATIC reviews ,BRONCHIAL disease diagnosis ,DIAPHRAGM (Anatomy) ,DIFFERENTIAL diagnosis ,MAGNETIC resonance imaging ,SURGERY - Abstract
Bronchogenic cysts (BC) are congenital abnormalities that occur most commonly within the mediastinum, and rarely occur within the diaphragm. We present the 21st case of an intradiaphragmatic bronchogenic cyst in the English literature, and review all previous published cases. Analysis includes presenting clinical symptoms, relevant radiologic studies, surgical approaches to resection, and management of the diaphragm, among other relevant data. These lesions should remain on the differential diagnosis in cases of unusual masses in the region of the diaphragm. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. Lung cancer screening in a community setting: Medicare patients have similar outcomes to younger patients
- Author
-
Balinger, Chris, Tolentino, Julia C., Birriel, T. Javier, Marchiagiani, Raffaele j., Gilbert, Victoria, Burfeind, William, Halpern, Andrew E., and Puc, Matthew
- Published
- 2015
- Full Text
- View/download PDF
21. Esophageal stenting in the setting of malignancy.
- Author
-
Martinez, Juan Carlos, Puc, Matthew M., and Quiros, Roderick M.
- Subjects
- *
ESOPHAGEAL cancer , *PATIENTS , *SURGICAL stents , *METASTASIS , *CANCER - Abstract
Esophageal cancer is often diagnosed at an advanced stage, with many patients found to have locoregional or metastatic disease at time of diagnosis. Because of this, cure may be unlikely, leading treatment efforts to focus more on symptom palliation and improving patient quality of life. The majority of patients with advanced disease suffer from some degree of dysphagia. Palliative efforts are therefore directed at relieving dysphagia, allowing patients to manage their oropharyngeal secretions, reduce aspiration risk, and maintain caloric intake orally. A variety of endoscopic treatment modalities have been utilized with these objectives in mind, with options determined by the location and size of the tumor, as well as the patient's expected prognosis. In this article, we review the use of endoscopically-placed stents for palliation in patients with advanced esophageal cancer. We discuss the history of stent use in such cases, as well as more recent developments in stent technology. We give an overview of some of the more commonly used stents in practice, discuss the technique of insertion, and survey the short- and long-term outcomes of stent placement. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
22. Ultrasound Is Not a Useful Screening Tool for Acute Acalculous Cholecystitis in Critically Ill Trauma Patients.
- Author
-
Puc, Matthew M., Tran, Hoang S., Wry, Philip W., and Ross, Steven E.
- Subjects
- *
DIAGNOSTIC ultrasonic imaging , *CHOLECYSTITIS , *DIAGNOSIS - Abstract
Acute acalculous cholecystitis remains a diagnostic challenge in critically ill trauma patients. Laboratory studies are nonspecific and associated injuries or mental status changes may mask clinical signs and symptoms. We conducted a retrospective study to assess the utility of ultrasound in the diagnosis of acute acalculous cholecystitis. We hypothesized that ultrasound is inadequate as a screening tool for acute acalculous cholecystitis. The abdominal ultrasounds of all patients undergoing evaluation for acute acalculous cholecystitis in a 40-month period at our Level I trauma center were reviewed. Thickened gallbladder wall, pericholecystic fluid and emphysematous gallbladder were considered positive sonographic criteria. Sludge, cholelithiasis, and hydrops were considered suggestive. Patients who did not undergo cholecystectomy had their gallbladders evaluated either during subsequent laparotomy or at autopsy or they were discharged from the hospital without need for intervention. Sixty-two patients were included. Twenty-one patients underwent cholecystectomy for presumed acute acalculous cholecystitis. The data revealed a sensitivity of 30 per cent (6/20) and a specificity of 93 per cent (39/42) for ultrasound evaluation. Twenty patients had subsequent hepatobiliary scans [hepato-iminodiacetic acid (HIDA)] with a sensitivity of 100 per cent (12/12) and specificity of 88 per cent (7/8). Our data do not support ultrasound as a reliable routine screening tool for acute acalculous cholecystitis. Despite its convenience as a bedside procedure ultrasound has insufficient sensitivity to justify its use and a more sensitive diagnostic tool should be used. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
23. A Novel Technique in a Sheep Model for Evaluating Prosthetic Heart Valve Performance.
- Author
-
Puc, Matthew M., Marra, Steven W., Tran, Hoang S., Cilley Jr., Jonathan H., Hewitt, Charles W., and Delrossi, Anthony J.
- Subjects
- *
PROSTHETIC heart valves , *PARAPLEGIA , *HEMORRHAGE complications - Abstract
There have been many various animal studies to evaluate the structural integrity and antithrombogenicity of prosthetic heart valves. We were interested in developing a novel sheep model to study the thrombogenicity of mechanical heart valves placed into the systemic circulation but without the need for cardiac bypass. Also, we wanted to minimize the risk of paraplegia from complete thoracic aortic clamping. Six sheep underwent left lateral thoracotomy for placement of a mechanical heart valve in parallel with the descending thoracic aorta. A valved conduit with a dacron tube graft sutured to the back end was fashioned. Employing partial aortic occlusion with a side-biting clamp, the proximal and distal ends were anastomosed in an end-to-side fashion. Once flow was confirmed through the graft, the native aorta was occulded with umbilical tape. The sheep received no postoperative anticoagulation. The median operative time and estimated blood loss (EBL) was 170 min and 250 cc, respectively. Patency of the valved conduits was confirmed during the initial procedure, and there was no incidence of paraplegia postoperatively. Two animals expired shortly after extubation and at necropsy the valved conduits were patent with preserved valve function. The four survivors were sacrificed a median of 37 days postoperatively. Prior to euthanasia, the valved conduits were evaluated in situ with ultrasound. In all cases, the valves had clot formation at the hinges, which prevented active movement of the leaflets. This novel in vivo technique provides an alternative in testing the thrombogenicity of prosthetic heart valves without cardiac bypass or the risk of paraplegia in an animal that is extremely sensitive to complete aortic cross-clamp. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
24. Multiple Oblique Illumination and High-Definition Microscopy for Breast Fine-Needle Aspirates.
- Author
-
Puc, Matthew M., Chrzanowski Jr., Francis A., Tran, Hoang, Geldziler, Brian, Martucci, Mary, Doolin, Edward J., and Hewitt, Charles W.
- Subjects
- *
NEEDLE biopsy of the breast , *MEDICAL microscopy - Abstract
The ability of multiple oblique illumination (MOI) and high-definition microscopy (Edge R-400 3-D microscope) to improve resolution of cellular detail in the evaluation of cytopathological specimens of Pap smears and thyroid fine-needle aspirates (FNAs) has been demonstrated. However, previous experiments showed that the advantages of MOI and high-definition stereo microscopy were less certain for the breast FNAs. We hypothesized that these findings were due to the lack of sample thickness for the breast FNA specimens. To test this hypothesis, we analyzed breast FNA specimens that were significantly thicker (10.5 μm). The number of lights (1, 2, 3, 4) and the angle of light (+1.5, 0, -3) were varied independently, creating 12 groups. Three images at each combination of settings were digitally captured and analyzed to obtain a histogram. The coefficient of resolution (C[sub r]) was calculated to mathematically evaluate the grayscale histograms for intensities (0-255), where C[sub r] = [| I[sub M] - I[sub N] | × (N)] (I[sub M], median pixel intensity; I[sub N], measured pixel intensity; and N, number of pixels at given intensity). Mean C[sub r] values demonstrated that the angle of light obliquity was not a factor in altering the resolution and contrast (p = .9). However, there was a significant increase in resolution, as measured by mean C[sub r] values, as the number of lights was successively reduced from four lights to one light. Thus, the thicker specimen did show that increases in resolution were a significant function of the number of lights utilized. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
25. THE CARDIOVASCULAR HEMODYNAMICS AND LEUKOTRIENE KINETICS DURING PROSTACYCLIN AND ANTI-PROSTACYCLIN ANTIBODY INFUSIONS IN SEPTIC SHOCK.
- Author
-
Tran, Hoang S., Quinn, James V., Puc, Matthew M., Woolley, Daniel S., Puglisi, Roberto N., and Slotman, Gus J.
- Published
- 2000
- Full Text
- View/download PDF
26. Transmyocardial Laser Revascularization: Current Status.
- Author
-
Puc, Matthew M., Levin, Steven, Tran, Hoang S., Marra, Steve, Hewitt, Charles W., and Rossi, Anthony J. Del
- Subjects
- *
TRANSMYOCARDIAL laser revascularization , *MYOCARDIAL revascularization - Abstract
Transmyocardial laser revascularization (TMLR) has been widely evaluated for treatment of the ischemic myocardium either in conjunction with coronary artery bypass grafting or as sole therapy. Clinically, it has shown significant improvement for angina symptoms, but the mechanism by which this modality works is unknown at this time. The original premise on which transmyocardial revascularization was established depended on its ability to essentially generate channels that would directly carry blood from the ventricle into the ischemic myocardium. This theory, however, has not been substantiated, so other mechanisms have been postulated. This article gives a historical perspective on the advent of transmyocardial revascularization and the many animal and human studies that have paved the way for its clinical use. Current controversies are examined, along with the new advances in laser technology and where the future of TMLR is headed. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
27. Efficacy of Jejunogram after Jejunostomy Insertion.
- Author
-
Puc, Matthew M. and Tran, Hoang
- Subjects
- *
JEJUNOSTOMY , *HUMAN abnormalities , *JEJUNUM - Abstract
The era of managed care has spawned a national debate over the allocation of health care resources. We hypothesized that routine postjejunostomy jejunogram rarely provides additional clinical information or changes patient management and, therefore, is unwarranted. We retrospectively reviewed the charts of 128 consecutive patients undergoing feeding jejunostomy tube insertion between January 1995 and December 1996. All patients had postinsertion jejunograms. Eighty-five (66%) of the jejunograms were performed after operative insertion of the jejunostomy, and 43 (33%) were performed after percutaneous reinsertion of a previously placed jejunostomy. Data extracted from the charts include age, sex, indication for jejunogram, length of time prior jejunostomy was in place at time of reinsertion, and results of jejunogram. There were no patients (0%) with misplaced jejunostomy or extravasation of dye, as noted on jejunogram. There were no management changes implemented as a result of jejunogram readings (P < <0.05). The use of routine jejunogram after operative insertion or reinsertion of a prior jejunostomy that has become dislodged or occluded does not alter patient management, incurs unnecessary costs, and, therefore, is unwarranted. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
28. Inflammatory response after bioglue application: Reply
- Author
-
Hewitt, Charles W., Marra, Steven W., Kann, Brian R., Tran, Hoang S., Puc, Matthew M., Chrzanowski, Frank A., Jr, Tran, Jean-Luc V., Cilley, Jonathan H., Jr, Simonetti, Vincent A., DelRossi, Anthony J., and Lenz, Steven D.
- Published
- 2002
- Full Text
- View/download PDF
29. Age-Adjusted Outcomes in Traumatic Flail Chest Injuries in the Elderly.
- Author
-
Albaugh, Gregory, Kann, Brian, Puc, Matthew M., Vemulapalli, Pratibha, Marra, Steven, and Ross, Steven
- Subjects
- *
OLDER people's injuries , *CHEST injuries , *TRAUMATISM - Abstract
Severe chest trauma does not independently predict poor outcome in elderly patients. We chose a specific injury, flail chest, to determine whether age factored into outcome of these patients. A retrospective chart review of all trauma admissions to our Level I trauma center between January 1994 and January 1998 sustaining flail chest was undertaken. Sixty-eight patients were identified, but ten patients were excluded because of death on arrival. Fifty-eight patients were included in the study and separated into groups. The first group comprised those under the age of 55 (n = 32) and the second comprised those over age 55 (n = 26). Parameters evaluated were age, Injury Severity Score (ISS), neurologic injury, the need for mechanical ventilation, need for tracheostomy, length of stay, and death. Statistical analysis was performed with Wilcoxon t test, chi[sup 2], and logistic regression where appropriate. A 95 per cent confidence interval was sought as determinant of significance. Of the 58 surviving patients analyzed there was no significant difference between the groups regarding ISS, length of stay, days on the ventilator, head injury, tracheostomy, or development of pneumonia or adult respiratory distress syndrome. The likelihood of death was shown to increase by 132 per cent for every 10 years starting at the second decade and continuing to the eighth decade of life. The likelihood of death also increased by 30 per cent for each unit increase in ISS. The likelihood of death decreased by 23 per cent for every day survived in the hospital. Blunt chest trauma directly impacts respiratory mechanics. Elderly patients are more likely to have comorbid conditions and less likely to tolerate traumatic respiratory compromise. Age (and its effects on the body) is the strongest predictor of outcome with flail chest and is associated with an increased mortality (P less than or equal to 0.05). [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
30. The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
- Author
-
Castellano CA, Sun T, Ravindranathan D, Hwang C, Balanchivadze N, Singh SRK, Griffiths EA, Puzanov I, Ruiz-Garcia E, Vilar-Compte D, Cárdenas-Delgado AI, McKay RR, Nonato TK, Ajmera A, Yu PP, Nadkarni R, O'Connor TE, Berg S, Ma K, Farmakiotis D, Vieira K, Arvanitis P, Saliby RM, Labaki C, El Zarif T, Wise-Draper TM, Zamulko O, Li N, Bodin BE, Accordino MK, Ingham M, Joshi M, Polimera HV, Fecher LA, Friese CR, Yoon JJ, Mavromatis BH, Brown JT, Russell K, Nanchal R, Singh H, Tachiki L, Moria FA, Nagaraj G, Cortez K, Abbasi SH, Wulff-Burchfield EM, Puc M, Weissmann LB, Bhatt PS, Mariano MG, Mishra S, Halabi S, Beeghly A, Warner JL, French B, and Bilen MA
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Severity of Illness Index, Respiration, Artificial statistics & numerical data, COVID-19 mortality, COVID-19 complications, COVID-19 epidemiology, COVID-19 pathology, Registries, Neoplasm Metastasis, Hospitalization statistics & numerical data, Neoplasms pathology, Neoplasms mortality, SARS-CoV-2 isolation & purification
- Abstract
Background: COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID-19 outcomes., Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, the authors identified 10,065 patients with COVID-19 and cancer (2325 with and 7740 without metastasis at the time of COVID-19 diagnosis). The primary ordinal outcome was COVID-19 severity: not hospitalized, hospitalized but did not receive supplemental O
2 , hospitalized and received supplemental O2 , admitted to an intensive care unit, received mechanical ventilation, or died from any cause. The authors used ordinal logistic regression models to compare COVID-19 severity by presence and specific site of metastatic cancer. They used logistic regression models to assess 30-day all-cause mortality., Results: Compared to patients without metastasis, patients with metastases have increased hospitalization rates (59% vs. 49%) and higher 30 day mortality (18% vs. 9%). Patients with metastasis to bone, lung, liver, lymph nodes, and brain have significantly higher COVID-19 severity (adjusted odds ratios [ORs], 1.38, 1.59, 1.38, 1.00, and 2.21) compared to patients without metastases at those sites. Patients with metastasis to the lung have significantly higher odds of 30-day mortality (adjusted OR, 1.53; 95% confidence interval, 1.17-2.00) when adjusting for COVID-19 severity., Conclusions: Patients with metastatic cancer, especially with metastasis to the brain, are more likely to have severe outcomes after COVID-19 whereas patients with metastasis to the lung, compared to patients with cancer metastasis to other sites, have the highest 30-day mortality after COVID-19., (© 2024 American Cancer Society.)- Published
- 2024
- Full Text
- View/download PDF
31. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.
- Author
-
Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, Lopes GL, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, and Shah DP
- Subjects
- United States epidemiology, Humans, Female, Middle Aged, SARS-CoV-2, Cohort Studies, Retrospective Studies, COVID-19, Breast Neoplasms epidemiology
- Abstract
Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations., Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity., Results: 1383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32-1.67]); Black patients (aOR 1.74; 95 CI 1.24-2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70-6.79) and Other (aOR 2.97; 95 CI 1.71-5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83-12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63-3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20-2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66-3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89-22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status., Conclusions: Using one of the largest registries on cancer and COVID-19, we identified patient and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to non-Hispanic White patients., Funding: This study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay Mishra, Benjamin French, Jeremy L Warner; P30-CA046592 to Christopher R Friese; P30 CA023100 for Rana R McKay; P30-CA054174 for Pankil K Shah and Dimpy P Shah; KL2 TR002646 for Pankil Shah and the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE) and P30-CA054174 for Dimpy P Shah. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication., Clinical Trial Number: CCC19 registry is registered on ClinicalTrials.gov, NCT04354701., Competing Interests: GN, SV, AK, TS, NK, DA, JA, JA, ZB, NB, TB, BB, SB, MB, PB, SB, BB, HB, CC, HC, JD, AD, NE, LF, DF, CF, MG, CG, PG, SG, MH, HH, DH, CH, CJ, SJ, MJ, VK, EK, NK, VK, AK, DK, CL, PL, KL, ML, XL, GL, GL, DM, AM, MM, SM, RM, IM, VM, RN, SN, RN, TN, TO, OP, KP, JP, KP, JP, HP, MP, YR, PR, SR, JR, DR, MR, SR, AR, LS, PS, MS, LS, MS, DS, MS, LT, MT, ST, LW, GW, MW, EW, SM, BF, JW, ML, MA, DS No competing interests declared
- Published
- 2023
- Full Text
- View/download PDF
32. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
- Author
-
Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, Griffiths EA, Hwang C, Jani C, Joshi M, Khan H, Klein EJ, Heater NK, Koshkin VS, Kwon DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasone ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E, Saliby RM, Shastri A, Singh SRK, Tagalakis V, Vilar-Compte D, Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warner JL, Connors JM, Shah DP, and Rosovsky RP
- Subjects
- Humans, Male, Aged, Female, Anticoagulants therapeutic use, Cohort Studies, Retrospective Studies, COVID-19 Testing, Vascular Endothelial Growth Factor A, SARS-CoV-2, Immunomodulating Agents, COVID-19, Venous Thromboembolism chemically induced, Venous Thromboembolism epidemiology, Neoplasms complications, Neoplasms drug therapy, Neoplasms epidemiology
- Abstract
Importance: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking., Objective: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer., Design, Setting, and Participants: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022., Exposure: Treatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19., Main Outcomes and Measures: Main outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up., Results: Of 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing cancer (aRR, 1.43; 95% CI, 1.01-2.03), history of VTE (aRR, 3.10; 95% CI, 2.38-4.04), and high-risk site of cancer (aRR, 1.42; 95% CI, 1.14-1.75). Black patients had a higher risk of TEEs (aRR, 1.24; 95% CI, 1.03-1.50) than White patients. Patients with TEEs had high intensive care unit admission (46%) and mechanical ventilation (31%) rates. Relative risk of death in patients with TEEs was higher in those exposed to TOIs vs not (aRR, 1.12; 95% CI, 0.91-1.38) and was significantly associated with poor performance status (aRR, 1.77; 95% CI, 1.30-2.40) and active/progressing cancer (aRR, 1.55; 95% CI, 1.13-2.13)., Conclusions and Relevance: In this cohort study, relative risk of developing VTE was high among patients receiving TOIs and varied by the type of therapy, underlying risk factors, and demographics, such as race and ethnicity. These findings highlight the need for close monitoring and perhaps personalized thromboprophylaxis to prevent morbidity and mortality associated with COVID-19-related thromboembolism in patients with cancer.
- Published
- 2023
- Full Text
- View/download PDF
33. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
- Author
-
Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, and Wise-Draper TM
- Subjects
- Humans, Female, Middle Aged, Aged, Male, SARS-CoV-2, Cohort Studies, Retrospective Studies, COVID-19 Testing, Cytokine Release Syndrome etiology, Immunosuppression Therapy, Immunotherapy adverse effects, COVID-19 epidemiology, Neoplasms epidemiology, Neoplasms therapy
- Abstract
Importance: Cytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation., Objective: To determine the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer., Design, Setting, and Participants: This registry-based retrospective cohort study included 12 046 patients reported to the COVID-19 and Cancer Consortium (CCC19) registry from March 2020 to May 2022. The CCC19 registry is a centralized international multi-institutional registry of patients with COVID-19 with a current or past diagnosis of cancer. Records analyzed included patients with active or previous cancer who had a laboratory-confirmed infection with SARS-CoV-2 by polymerase chain reaction and/or serologic findings., Exposures: Immunosuppression due to therapy; systemic anticancer therapy (IO or non-IO)., Main Outcomes and Measures: The primary outcome was a 5-level ordinal scale of COVID-19 severity: no complications; hospitalized without requiring oxygen; hospitalized and required oxygen; intensive care unit admission and/or mechanical ventilation; death. The secondary outcome was the occurrence of cytokine storm., Results: The median age of the entire cohort was 65 years (interquartile range [IQR], 54-74) years and 6359 patients were female (52.8%) and 6598 (54.8%) were non-Hispanic White. A total of 599 (5.0%) patients received IO, whereas 4327 (35.9%) received non-IO systemic anticancer therapies, and 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior to COVID-19 diagnosis. Although no difference in COVID-19 severity and cytokine storm was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio [aOR], 0.80; 95% CI, 0.56-1.13, and aOR, 0.89; 95% CI, 0.41-1.93, respectively), patients with baseline immunosuppression treated with IO (vs untreated) had worse COVID-19 severity and cytokine storm (aOR, 3.33; 95% CI, 1.38-8.01, and aOR, 4.41; 95% CI, 1.71-11.38, respectively). Patients with immunosuppression receiving non-IO therapies (vs untreated) also had worse COVID-19 severity (aOR, 1.79; 95% CI, 1.36-2.35) and cytokine storm (aOR, 2.32; 95% CI, 1.42-3.79)., Conclusions and Relevance: This cohort study found that in patients with cancer and COVID-19, administration of systemic anticancer therapies, especially IO, in the context of baseline immunosuppression was associated with severe clinical outcomes and the development of cytokine storm., Trial Registration: ClinicalTrials.gov Identifier: NCT04354701.
- Published
- 2023
- Full Text
- View/download PDF
34. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.
- Author
-
Rubinstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordino M, Assouline SE, Awosika J, Bakouny Z, Bashir B, Berg S, Bilen MA, Castellano CA, Cogan JC, Kc D, Friese CR, Gupta S, Hausrath D, Hwang C, Johnson NA, Joshi M, Kasi A, Klein EJ, Koshkin VS, Kuderer NM, Kwon DH, Labaki C, Latif T, Lau E, Li X, Lyman GH, McKay RR, Nagaraj G, Nizam A, Nonato TK, Olszewski AJ, Polimera HV, Portuguese AJ, Puc MM, Razavi P, Rosovski R, Schmidt A, Shah SA, Shastri A, Su C, Torka P, Wise-Draper TM, Zubiri L, Warner JL, and Thompson MA
- Subjects
- COVID-19 Testing, Humans, Risk Factors, SARS-CoV-2, COVID-19 epidemiology, Lymphatic Diseases, Neoplasms epidemiology
- Abstract
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19., Significance: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
35. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.
- Author
-
Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, Goel S, Gomez CG, Grant KL, Griffiths EA, Gulati S, Gupta S, Hwang C, Jain J, Jani C, Kaltsas A, Kasi A, Khan H, Knox N, Koshkin VS, Kwon DH, Labaki C, Lyman GH, McKay RR, McNair C, Nagaraj G, Nakasone ES, Nguyen R, Nonato TK, Olszewski AJ, Panagiotou OA, Puc M, Razavi P, Robilotti EV, Santos-Dutra M, Schmidt AL, Shah DP, Shah SA, Vieira K, Weissmann LB, Wise-Draper TM, Wu U, Wu JT, Choueiri TK, Mishra S, Warner JL, French B, and Farmakiotis D
- Abstract
Background: The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection., Methods: We included adult (≥18 years) patients with active or prior hematologic or invasive solid malignancies and laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, using data from the COVID-19 and Cancer Consortium (CCC19, NCT04354701). We captured coinfections within ±2 weeks from diagnosis of COVID-19, identified factors cross-sectionally associated with risk of coinfection, and quantified the association of coinfections with 30-day mortality., Results: Among 8765 patients (hospitalized or not; median age, 65 years; 47.4% male), 16.6% developed coinfections: 12.1% bacterial, 2.1% viral, 0.9% fungal. An additional 6.4% only had clinical diagnosis of a coinfection. The adjusted risk of any coinfection was positively associated with age >50 years, male sex, cardiovascular, pulmonary, and renal comorbidities, diabetes, hematologic malignancy, multiple malignancies, Eastern Cooperative Oncology Group Performance Status, progressing cancer, recent cytotoxic chemotherapy, and baseline corticosteroids; the adjusted risk of superinfection was positively associated with tocilizumab administration. Among hospitalized patients, high neutrophil count and C-reactive protein were positively associated with bacterial coinfection risk, and high or low neutrophil count with fungal coinfection risk. Adjusted mortality rates were significantly higher among patients with bacterial (odds ratio [OR], 1.61; 95% CI, 1.33-1.95) and fungal (OR, 2.20; 95% CI, 1.28-3.76) coinfections., Conclusions: Viral and fungal coinfections are infrequent among patients with cancer and COVID-19, with the latter associated with very high mortality rates. Clinical and laboratory parameters can be used to guide early empiric antimicrobial therapy, which may improve clinical outcomes., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
36. Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
- Author
-
Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, and Hwang C
- Subjects
- Aged, Cause of Death, Censuses, Female, Health Facilities, Humans, Intensive Care Units, Male, Middle Aged, Odds Ratio, Registries, Respiration, Artificial, Retrospective Studies, Risk Factors, SARS-CoV-2, Severity of Illness Index, Spatial Analysis, United States epidemiology, COVID-19 epidemiology, Neoplasms epidemiology, Pandemics, Rural Population, Social Vulnerability, Urban Population
- Abstract
Importance: The COVID-19 pandemic has had a distinct spatiotemporal pattern in the United States. Patients with cancer are at higher risk of severe complications from COVID-19, but it is not well known whether COVID-19 outcomes in this patient population were associated with geography., Objective: To quantify spatiotemporal variation in COVID-19 outcomes among patients with cancer., Design, Setting, and Participants: This registry-based retrospective cohort study included patients with a historical diagnosis of invasive malignant neoplasm and laboratory-confirmed SARS-CoV-2 infection between March and November 2020. Data were collected from cancer care delivery centers in the United States., Exposures: Patient residence was categorized into 9 US census divisions. Cancer center characteristics included academic or community classification, rural-urban continuum code (RUCC), and social vulnerability index., Main Outcomes and Measures: The primary outcome was 30-day all-cause mortality. The secondary composite outcome consisted of receipt of mechanical ventilation, intensive care unit admission, and all-cause death. Multilevel mixed-effects models estimated associations of center-level and census division-level exposures with outcomes after adjustment for patient-level risk factors and quantified variation in adjusted outcomes across centers, census divisions, and calendar time., Results: Data for 4749 patients (median [IQR] age, 66 [56-76] years; 2439 [51.4%] female individuals, 1079 [22.7%] non-Hispanic Black individuals, and 690 [14.5%] Hispanic individuals) were reported from 83 centers in the Northeast (1564 patients [32.9%]), Midwest (1638 [34.5%]), South (894 [18.8%]), and West (653 [13.8%]). After adjustment for patient characteristics, including month of COVID-19 diagnosis, estimated 30-day mortality rates ranged from 5.2% to 26.6% across centers. Patients from centers located in metropolitan areas with population less than 250 000 (RUCC 3) had lower odds of 30-day mortality compared with patients from centers in metropolitan areas with population at least 1 million (RUCC 1) (adjusted odds ratio [aOR], 0.31; 95% CI, 0.11-0.84). The type of center was not significantly associated with primary or secondary outcomes. There were no statistically significant differences in outcome rates across the 9 census divisions, but adjusted mortality rates significantly improved over time (eg, September to November vs March to May: aOR, 0.32; 95% CI, 0.17-0.58)., Conclusions and Relevance: In this registry-based cohort study, significant differences in COVID-19 outcomes across US census divisions were not observed. However, substantial heterogeneity in COVID-19 outcomes across cancer care delivery centers was found. Attention to implementing standardized guidelines for the care of patients with cancer and COVID-19 could improve outcomes for these vulnerable patients.
- Published
- 2022
- Full Text
- View/download PDF
37. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
- Author
-
Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, Faller B, Gao X, Gartrell BA, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki AR, Menon H, Morris MJ, Puc M, Russell KB, Shah NJ, Sharifi N, Shaya J, Schweizer MT, Steinharter J, Wulff-Burchfield EM, Xu W, Zhu J, Mishra S, Grivas P, Rini BI, Warner JL, Zhang T, Choueiri TK, Gupta S, and McKay RR
- Subjects
- Aged, Aged, 80 and over, Androgen Antagonists therapeutic use, COVID-19 epidemiology, COVID-19 mortality, Cohort Studies, Humans, Male, Middle Aged, Prostatic Neoplasms epidemiology, Risk Factors, Tennessee epidemiology, Androgen Antagonists adverse effects, COVID-19 complications, Prostatic Neoplasms drug therapy, Prostatic Neoplasms mortality
- Abstract
Importance: Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in the tissue-based expression of the SARS-CoV-2 coreceptor transmembrane protease, serine 2 (TMPRSS2)., Objective: To examine whether ADT is associated with a decreased rate of 30-day mortality from SARS-CoV-2 infection among patients with prostate cancer., Design, Setting, and Participants: This cohort study analyzed patient data recorded in the COVID-19 and Cancer Consortium registry between March 17, 2020, and February 11, 2021. The consortium maintains a centralized multi-institution registry of patients with a current or past diagnosis of cancer who developed COVID-19. Data were collected and managed using REDCap software hosted at Vanderbilt University Medical Center in Nashville, Tennessee. Initially, 1228 patients aged 18 years or older with prostate cancer listed as their primary malignant neoplasm were included; 122 patients with a second malignant neoplasm, insufficient follow-up, or low-quality data were excluded. Propensity matching was performed using the nearest-neighbor method with a 1:3 ratio of treated units to control units, adjusted for age, body mass index, race and ethnicity, Eastern Cooperative Oncology Group performance status score, smoking status, comorbidities (cardiovascular, pulmonary, kidney disease, and diabetes), cancer status, baseline steroid use, COVID-19 treatment, and presence of metastatic disease., Exposures: Androgen deprivation therapy use was defined as prior bilateral orchiectomy or pharmacologic ADT administered within the prior 3 months of presentation with COVID-19., Main Outcomes and Measures: The primary outcome was the rate of all-cause 30-day mortality after COVID-19 diagnosis for patients receiving ADT compared with patients not receiving ADT after propensity matching., Results: After exclusions, 1106 patients with prostate cancer (before propensity score matching: median age, 73 years [IQR, 65-79 years]; 561 (51%) self-identified as non-Hispanic White) were included for analysis. Of these patients, 477 were included for propensity score matching (169 who received ADT and 308 who did not receive ADT). After propensity matching, there was no significant difference in the primary end point of the rate of all-cause 30-day mortality (OR, 0.77; 95% CI, 0.42-1.42)., Conclusions and Relevance: Findings from this cohort study suggest that ADT use was not associated with decreased mortality from SARS-CoV-2 infection. However, large ongoing clinical trials will provide further evidence on the role of ADT or other androgen-targeted therapies in reducing COVID-19 infection severity.
- Published
- 2021
- Full Text
- View/download PDF
38. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
- Author
-
Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G Jr, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshow DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, and Warner JL
- Subjects
- Adenosine Monophosphate analogs & derivatives, Adenosine Monophosphate therapeutic use, Age Factors, Aged, Alanine analogs & derivatives, Alanine therapeutic use, Betacoronavirus pathogenicity, COVID-19, Clinical Decision-Making, Coronavirus Infections complications, Coronavirus Infections diagnosis, Coronavirus Infections mortality, Drug Therapy, Combination methods, Drug Therapy, Combination statistics & numerical data, Follow-Up Studies, Glucocorticoids therapeutic use, Hospital Mortality, Humans, Hydroxychloroquine therapeutic use, Male, Middle Aged, Neoplasms complications, Pandemics, Pneumonia, Viral complications, Pneumonia, Viral diagnosis, Pneumonia, Viral mortality, Risk Factors, SARS-CoV-2, Severity of Illness Index, Sex Factors, Treatment Outcome, United States epidemiology, COVID-19 Drug Treatment, Coronavirus Infections drug therapy, Drug Utilization statistics & numerical data, Healthcare Disparities statistics & numerical data, Neoplasms mortality, Pneumonia, Viral drug therapy
- Abstract
Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. SIGNIFICANCE: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access. This article is highlighted in the In This Issue feature, p. 1426 ., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
39. Preoperative CHA2DS2-VASc Score Predicts Postoperative Atrial Fibrillation after Lobectomy.
- Author
-
Lee CT, Strauss DM, Stone LE, Stoltzfus JC, Puc MM, and Burfeind WR
- Subjects
- Age Factors, Aged, Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Carcinoma, Non-Small-Cell Lung pathology, Clinical Decision-Making, Comorbidity, Databases, Factual, Female, Health Status, Humans, Lung Neoplasms pathology, Male, Middle Aged, Pennsylvania, Pneumonectomy methods, Predictive Value of Tests, Retrospective Studies, Risk Assessment, Risk Factors, Sex Factors, Treatment Outcome, Atrial Fibrillation etiology, Carcinoma, Non-Small-Cell Lung surgery, Decision Support Techniques, Lung Neoplasms surgery, Pneumonectomy adverse effects, Thoracic Surgery, Video-Assisted adverse effects
- Abstract
Background: Postoperative atrial fibrillation (POAF) affects 10 to 20% of noncardiac thoracic surgeries and increases patient morbidity and costs. The purpose of this study is to determine if preoperative CHA
2 DS2 -VASc score can predict POAF after pulmonary lobectomy for nonsmall cell lung cancer., Methods: Patients with complete CHA2 DS2 -VASc data who underwent lobectomies from January 2007 to January 2016 at a single institution were analyzed in a retrospective case-control study using a prospective database. An independent samples t -test was used to compare the mean CHA2 DS2 -VASc scores of POAF and non-POAF groups. A multivariable logistic regression analysis (MVA) evaluated the independent contribution of variables of the CHA2 DS2 -VASc score in predicting POAF. Chi-square test with univariate odds ratios (ORs) was used to determine a statistically significant cutoff score for predicting POAF., Results: Of 525 total patients, 82 (15.6%) developed POAF (mean CHA2 DS2 -VASc score: 2.7) and 443 (84.4%) did not develop POAF (mean score: 2.3). Mean difference between these groups was significant at 0.43 ( p = 0.01; 95% confidence interval [CI]: 0.09-0.76). In the MVA, significant predictors of POAF were age 65 to 74 years (adjusted OR [aOR] = 2.45; 95% CI: 1.31-4.70; p = 0.006) and age ≥75 years (aOR = 3.11; 95% CI: 1.62-5.95; p = 0.0006). Patients with CHA2 DS2 -VASc scores ≥5 had significantly increased OR for POAF (OR = 2.59; 95% CI: 1.22-5.50)., Conclusions: Preoperatively calculated CHA2 DS2 -VASc score can predict POAF in patients undergoing pulmonary lobectomy. Age is the most statistically significant independent predictor, and patients with scores ≥5 have significantly increased risk. Trials for POAF prophylaxis should target this population., Competing Interests: Disclosure The authors report no conflicts of interest in this work., (Georg Thieme Verlag KG Stuttgart · New York.)- Published
- 2019
- Full Text
- View/download PDF
40. Early outcomes after bilateral thoracoscopy versus median sternotomy for lung volume reduction.
- Author
-
Puc MM, Sonnad SS, and Shrager JB
- Abstract
Objective: : A National Emphysema Treatment Trial subanalysis, although finally describing outcomes as "comparable," suggested that bilateral lung volume reduction surgery (LVRS) by video-assisted thoracoscopic surgery (VATS) may be slightly less morbid than by median sternotomy (MS). We report a single surgeon experience using both the MS and VATS approaches to provide additional information on this issue in a setting of uniform patient selection and perioperative management. Our hypothesis was that a VATS approach would provide equivalent or less morbidity than MS despite being applied to a group of patients subjectively selected to be higher risk than those undergoing MS., Methods: : Consecutive patients over a 9-year period underwent LVRS by one surgeon by either MS or VATS in a nonrandomized fashion. Thoracoscopy was selected over MS primarily when the surgeon estimated a greater overall risk profile and thus a greater chance of morbidity/mortality in a particular patient., Results: : There were 15 patients in the VATS group and 35 in the MS group. In terms of measures of risk profile, there were no differences between the groups that met statistical significance, but several values trended toward higher risk within the VATS group (eg, age, 63 VATS vs. 59 MS, P = 0.08; moderate pulmonary hypertension, 38% VATS vs. 14% MS, P = 0.11; and residual volume, 241% VATS vs. 226% MS, P = 0.32). With regard to outcomes, operative time was significantly longer in the VATS group (VATS = 155 minutes vs. MS=129 minutes, P = 0.01). All other outcomes, including the incidence of major complications (13.3% VATS vs. 17.1% MS, P = 0.39), were similar between the groups. There was a single death within 90 days (1.9% of entire series; 2.9% of MS group)., Conclusions: : In this series, although patients undergoing LVRS by VATS tended to have a higher risk profile, their outcomes were no worse than in those undergoing LVRS by MS. This suggests that the VATS approach to bilateral LVRS may incur slightly less morbidity and thus may be the best option in the most compromised patients who is nonetheless felt will benefit from LVRS.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.